UBS analyst AJ Rice upgraded Aveanna (AVAH) to Neutral from Sell with a price target of $8, up from $6.75. The company’s leverage trajectory has more visibility and the impacts of the interest rate swaps/caps are better understood, the analyst tells investors in a research note. The outsized earnings performance year-to-date creates a trajectory that allows for the company to accelerate the path forward to getting to a reasonable leverage ratio, UBS says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH:
- Aveanna upgraded to Overweight from Equal Weight at Barclays
- Aveanna Healthcare’s Earnings Call Highlights Growth and Optimism
- Aveanna price target raised to $6.75 from $5 at UBS
- Aveanna upgraded to Outperform from Market Perform at Raymond James
- Aveanna Healthcare Highlights Strong Financial Performance